Listing & Compliance Notices

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding other.

“January 29, 2026, after considering the written record in this matter, the Council issued its decision affirming the Panel’s decision to delist the Company’s securities from Nasdaq. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 3, 2026 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2”

Marwynn Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 29, 2026, Marwynn Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the last 30 consecutive business days from December 15, 2025 to January 28, 2026, the Company no longer meets the minimum bid price requirement set forth in the Listing Rules 5550(a)”

RCI HOSPITALITY HOLDINGS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“January 30, 2026, RCI Hospitality Holdings, Inc. (“we,” “us” and the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that we are not in compliance with Listing Rule 5250(c)(1) because we have failed to file our Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the “Form 10-K”). Under the Nasdaq Listing Rules, we have until March 31, 2026 to submit a plan to Nasdaq as to how we plan to regain compliance with Nasdaq’s continued listing requirements. Although we intend to regain”

Blink Charging Co. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

“stock, par value $0.001 per share (“Common Stock”), for the prior 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the continued listing status of the Common Stock on The Nasdaq Capital Market and, therefore, the Company’s listing remains fully effective. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided”

TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing R”

GENERATION INCOME PROPERTIES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 28, 2026, Generation Income Properties, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 27, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq”

Fat Brands, Inc received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“January 28, 2026, FAT Brands Inc. (the “ Company ”) received a letter (the “ Delisting Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1. Pursuant to the Delisting Notice, Nasdaq’s determination was based on (i) the Company’s commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code on January 26, 2026 (the “ Chapter 11 Cases ”) and associated public”

DocGo Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 26, 2026, DocGo Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from December 9, 2025 to January 23, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Requirement”).”

Tenaya Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a”

Spark I Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 27, 2026, Spark I Acquisition Corp. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5620(a), which requires companies listed on Nasdaq to hold an annual meeting of shareholders within twelve months of the end of the company’s fiscal year. The Notice has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days, or until M”

RenX Enterprises Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 26, 2026, RenX Enterprises Corp. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (December 5, 2025 through January 20, 2026), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The N”

Twin Hospitality Group Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“January 28, 2026, Twin Hospitality Group Inc. (the “ Company ”) received a letter (the “ Delisting Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Staff had determined that the Company’s Class A Common Stock (the “ Common Stock ”) will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1. Pursuant to the Delisting Notice, Nasdaq’s determination was based on (i) the Company’s commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code on January 26, 2026 (th”

Rithm Acquisition Corp. received a nyse deficiency notice notice regarding other (rules 802.01B).

“January 26, 2026, Rithm Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with Section 802.01B of the NYSE Listed Company Manual (the “Listing Rule”), which requires an NYSE-listed company to maintain a minimum of 300 public stockholders on a continuous basis. The Company will, within 45 days from the receipt of the Notice, submit a business plan to the NYSE that demonstrates how the Company expects to return to compliance with the Listing Rule within 18 months of receipt of the No”

Agape ATP Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 27, 2026, Agape ATP Corporation (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from December 10, 2025 to January 26, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Nasdaq has provided the Company with an 180 calendar days compliance period, or until July 27, 2026, in which to regain compliance with Nasdaq continued listi”

CIMG Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“January 22, 2026, CIMG Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) will consider an additional basis for the potential delisting of the Company’s securities from The Nasdaq Capital Market during the its panel monitor period because the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2025. In a decision letter dated December 4, 2025, the Panel imposed a Mandatory Panel Mo”

Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 15, 2026, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “”

KALA BIO, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 20, 2026, KALA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between December 3, 2025, to January 16, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“ Nasdaq ”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or unti”

Nexalin Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 21, 2026, Nexalin Technology, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid R”

REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).

“January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th”

Aprea Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock”

60 DEGREES PHARMACEUTICALS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5560(a)).

“January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. As disclosed in the Notice, Nasdaq staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2). While companies are typically afforded a 180-calen”

Pluri Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“January 20, 2026, Pluri Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires the Company to maintain a minimum of $35 million in market value of listed securities (“MVLS”) for continued listing on The Nasdaq Capital Market (the “MVLS Requirement”), nor is it in compliance with either of the alternative listing standards, including having stockholders’ equity of at least $2.5 million or net income of $5”

Bayview Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D), 5810(b), 5505).

“January 16, 2026, the Company received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rules 5450(b)(2)(C), 5810(c)(3)(D), 5810(b), and 5505 (collectively, the “MVPHS Rules”), which requires the Company to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $15.0 million. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s se”

INSPIRE VETERINARY PARTNERS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 13, 2025, Inspire Veterinary Partners, Inc. (the “Company”) received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). The Notice stated that the Company’s securities would be suspended from trading on The Nasdaq Capital Ma”

Advanced Biomed Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination by January 23, 2026 before a Hearings Panel (the “Panel”). On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company expects to present to the Pan”

Oak Woods Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 16, 2026, Oak Woods Acquisition Corporation (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year. The Nasdaq letter indicated that the Company did not hold an annual meeting of shareholders within twelve months following its fiscal year end and therefore no longer complies with this continued listing”

SYNLOGIC, INC. received a nasdaq delisting notice notice regarding other.

“January 16, 2026. As a result, on January 16, 2026, the Company received notice from Nasdaq that its shares will be suspended at the open of business on January 21, 2026. Nasdaq is expected to file a Form 25 Notification of Delisting with the Securities Exchange Commission when all internal procedural periods have run. The Company expects and plans for its shares of common stock to be quoted by the OTC Markets Group, Inc. (“OTC”) upon being delisted from Nasdaq. The Company will continue to remain a reporting company under the Securities Exchange Act of 1934, as amended, and the transition to”

Envirotech Vehicles, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 15, 2026, Envirotech Vehicles, Inc., a Delaware corporation (the “Company”), received a letter (the “Notice”) from the Listing Qualifications Department (the “Department”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, since the Company had not yet held its annual meeting of stockholders within twelve months of the Company’s fiscal year end, it no longer complied with Nasdaq Listing Rule 5620(a). Under Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days following receipt of the Notice, or until March 2, 2026, to submit a plan to regain compliance”

urban-gro, Inc. received a nasdaq extension granted notice regarding other (rules 5620(a)).

“January 13, 2026, the Panel notified the Company that it had granted a further extension to regain compliance with the Stockholders’ Equity Requirement, the Annual Meeting Requirement and the Timely Filing Requirement on or before February 17, 2026 and with the Bid Price Rule on or before February 24, 2026. There can be no assurance that the Company will be able to regain compliance with the Bid Price Rule, the Timely Filing Requirement, the Stockholders’ Equity Requirement or the Annual Meeting Requirement, or will otherwise be in compliance with other applicable Nasdaq Listing Rules. If the”

BT Brands, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 14, 2026, BT Brands, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the Company’s failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2024. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. The Notice states that the Company has un”

DT Cloud Star Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 15, 2026, DT Cloud Star Acquisition Corporation (the “Company”) received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in whi”

American Resources Corp received a nasdaq noncompliance notice notice regarding other (rules 5620(a)).

“January 13, 2026, American Resources Corporation (“AREC” or the “Company”) received a letter from Nasdaq Regulation (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The Company did not hold an annual meeting of shareholders within twelve months of its fiscal year ended December 31, 2024. The notice of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Marke”

Autonomix Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital”

ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 14, 2026, the Company received a letter from the Staff of Nasdaq (the “Nasdaq Notice”) indicating that it is not in compliance with Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”), which requires companies listed on Nasdaq to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year-end, and, as a result, does not currently satisfy the Annual Meeting Rule. The Staff indicated in the Nasdaq Notice that the Company’s non-compliance with the Annual Meeting Rule could be an additional basis for a delisting determination. The Company ac”

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5810(b)).

“assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance within any extension period granted by Nasdaq or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules. In accordance with Nasdaq Listing Rule 5810(b), the Company is required to disclose the receipt of the Nasdaq Letter. The Nasdaq Letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, which will continue to trade under the symbol “NRXP.” However, beginning five business days from the date of the”

Z Squared Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)).

“January 12, 2026, Coeptis Therapeutics Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Capital Market LLC (“Nasdaq”) indicating that the Company is in violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)G) due to the Company’s failure to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end of December 31, 2024 (the “Annual Meeting Rule”). Under Nasdaq Listing Rules, the Company has 45 calendar days from January 12, 2026 to submit a plan to regain compliance and, if Nasdaq accepts su”

GRI Bio, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“January 15, 2026, GRI Bio, Inc. (the “Company”) was formally notified by the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff has determined that the Company has conditionally regained compliance with the equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) which requires that companies listed on the Nasdaq Capital Market with a market value of less than $35 million and annual net income of less than $500,000 maintain stockholders’ equity of at least $2.5 million (the “Stockholders’ Equity Requirement”). As previously reported on the”

Borealis Foods Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 12, 2026, Borealis Foods Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The Notice indicates that the Company has 45 calendar days, or until February 26, 2026, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant the Company an exception of up to 180 calend”

ALPHA MODUS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 12, 2026, Alpha Modus Holdings, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum”

Fusemachines Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“January 15, 2026, Fusemachines Inc. (the “Company”) received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the continued listing requirement to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 for the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(C). Nasdaq’s determination was based on the Company’s MVPHS having been below $15,000,000 for the prior 30 consecutive business days from November 6, 2025 thro”

MICROVISION, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 12, 2026, MicroVision, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market (“Nasdaq”) advising that, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). The notification from Nasdaq is only a notification of deficiency, not of imminent delisting, and does not have a current effect on the listing or trading of the Company’s securities on Nasdaq. The Company is currently in compl”

FEMASYS INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 13, 2026, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to July 13, 2026 to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and July 13, 2026, and will consider available options to resolve the deficiency, including effecting a reverse stock split as stated above, and regain compliance with the Minimum Bid Price Requirement. SIGNATURE Pursuant to t”

Serina Therapeutics, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii), 1009).

“January 9, 2026, Serina Therapeutics, Inc. (the “Company”) received a notification (the “Letter”) from The NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of (i) $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, (ii) $4.0 million or more if the Company has reported losses”

Cambium Networks Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 9, 2026, Cambium Networks Corporation (the “Company”) received a staff determination letter (the “Determination Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) stating that because the Company did not hold an annual meeting of shareholders within twelve months from the Company's prior fiscal year end as required by Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”), the resulting non-compliance serves as an additional basis for delisting the Company's securities from The Nasdaq Global Market. The Determination Letter notified the Company that the Nasdaq hearing”

Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605).

“January 9, 2026, Tharimmune, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605 (“Rule 5605”), which requires, among other things, that a majority of the Board of Directors of the Company (the “Board”) be comprised of independent directors. As previously disclosed, Nancy Davis and Sanam Parikh resigned as members of the Board, effective as of November 6, 2025 and Mark Wendland was elected to replace Sanam Parikh, resulting in one vacancy on the Board and the noncompliance. In accordance with Nasdaq List”

ECD Automotive Design, Inc. received a nasdaq delisting notice notice regarding market value.

“January 15, 2026, the Company received a letter from the Staff stating that the Panel has determined to delist the Company’s securities, both common stock and warrants, from The Nasdaq Stock Market and that trading in the Company’s securities on The Nasdaq Stock Market will be suspended at the open of trading on January 16, 2026. The Company’s securities are expected to commence trading on the OTC Market commencing on January 16, 2025.”

ECD Automotive Design, Inc. received a nasdaq delisting notice notice regarding minimum bid price.

“January 15, 2026, the Company received a letter from the Staff stating that the Panel has determined to delist the Company’s securities, both common stock and warrants, from The Nasdaq Stock Market and that trading in the Company’s securities on The Nasdaq Stock Market will be suspended at the open of trading on January 16, 2026. The Company’s securities are expected to commence trading on the OTC Market commencing on January 16, 2025.”

STAAR SURGICAL CO received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(4)(B)).

“January 14, 2026, Elizabeth Yeu, MD resigned from the Board. Among other things, NASDAQ Listing Rule 5605 requires listed issuers such as the Company to maintain an audit committee consisting of no fewer than three independent directors. Dr. Yeu had been one of three independent directors on the Company’s Audit Committee at the time of her resignation, and therefore the Company does not presently comply with such requirement. In accordance with the Listing Rules, the Company notified NASDAQ on January 14, 2026 of such noncompliance and the Company’s intention to use the cure period provided un”

Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).

“January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 7, 2026, Estrella Immunopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a) because the Company has not held an annual meeting of shareholders within the required time period. The Letter also referenced the compliance plan procedures under Nasdaq Listing Rule 5810(c)(2)(G). The Letter states that the Company has 45 calendar days to submit a plan to regain compliance. The Company intends to submit its compliance”